JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

Home・Listă Acțiuni・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Deschisă

SectorSănătate

149.66 3.63

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

144.71

Maxim

150.4

Indicatori cheie
By Trading Economics
Venit	-60M -365M
Angajați	883
EBITDA	-59M -348M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+16.57% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	7.8B 28B
Deschiderea anterioară	146.03
Închiderea anterioară	149.66

Sentimentul știrilor

By Acuity

46%

54%

166 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

40.67 / 41.96 Suport & Rezistență

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 ian. 2026, 11:10 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 ian. 2026, 20:13 UTC

Principalele dinamici ale pieței

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 oct. 2025, 18:13 UTC

Principalele dinamici ale pieței

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 ian. 2026, 09:55 UTC

Acțiuni populare

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 ian. 2026, 19:30 UTC

Achiziții, Fuziuni, Preluări

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 ian. 2026, 19:30 UTC

Achiziții, Fuziuni, Preluări

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 ian. 2026, 19:30 UTC

Achiziții, Fuziuni, Preluări

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 ian. 2026, 19:58 UTC

Achiziții, Fuziuni, Preluări

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 ian. 2026, 14:54 UTC

Achiziții, Fuziuni, Preluări

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 ian. 2026, 10:54 UTC

Achiziții, Fuziuni, Preluări

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 ian. 2026, 14:49 UTC

Achiziții, Fuziuni, Preluări

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 ian. 2026, 12:38 UTC

Achiziții, Fuziuni, Preluări

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 ian. 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 ian. 2026, 20:29 UTC

Achiziții, Fuziuni, Preluări

AbbVie Near Deal for Revolution Medicines -- Update

7 ian. 2026, 19:48 UTC

Achiziții, Fuziuni, Preluări

Revolution Has Market Value of Around $16B -- WSJ

7 ian. 2026, 19:48 UTC

Achiziții, Fuziuni, Preluări

AbbVie Near Deal for Revolution Medicines -- WSJ

7 ian. 2026, 19:48 UTC

Achiziții, Fuziuni, Preluări

Deal May Come Soon, Sources Say -- WSJ

7 ian. 2026, 19:48 UTC

Achiziții, Fuziuni, Preluări

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

16.57% sus

Prognoză pe 12 luni

Medie 172.41 USD 16.57%

Maxim 263 USD

Minim 120 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor REVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

166 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.